DARZALEX 20 mg/mL concentrate for solution for infusion.

Company:
Janssen Sciences Ireland (a Johnson & Johnson Company)
Status:
Updated
Legal Category:
Product subject to medical prescription which may not be renewed (A)
Active Ingredient(s):
Daratumumab
*Additional information is available within the SPC or upon request to the company

Licence number

Strength

ATC code

Dosage form

EU/1/16/1101/001

100 mg in 5 mL

L01XC24

Concentrate for solution for infusion

EU/1/16/1101/002

400 mg in 20 mL

L01XC24

Concentrate for solution for infusion